As Taiwan begins administering two newly approved drugs for early-stage Alzheimer’s disease, more accurate diagnostic tools are needed to identify suitable patients and guide treatment decisions, medical experts said.
Kisunla, developed by US pharmaceutical company Eli Lilly, and Leqembi, jointly developed by Eisai in Japan, Biogen in the US and BioArctic in Sweden, were approved by the Food and Drug Administration (FDA) earlier this year for use.
The US Food and Drug Administration approved Kisunla last year and Leqembi in 2023.
Photo: CNA
Some patients in Taiwan began receiving the two drugs last week, but are doing so at their own expense, because the drugs are not covered by the National Health Insurance system.
A standard 18-month course for each of the two drugs costs about NT$1.5 million (US$51,405).
Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, Kaohsiung Chang Gung Memorial Hospital Department of Neurology deputy director Chang Chiung-chih (張瓊之) said.
To accurately identify the disease, doctors often need to spend a lot of time communicating with a new patient’s family and asking about the patient’s daily functioning, including asking whether they can still shop for groceries or perform basic calculations by themselves, Chang said.
With the two newly approved drugs for early-stage Alzheimer’s beginning to be administered across Taiwan, more accurate diagnostic tools are needed to identify patients in the early stages who are suitable for treatment, she said.
Researchers believe that Alzheimer’s disease is caused by the combined accumulation of amyloid and tau protein in the brain, and that the presence of tau protein is closely linked to the onset of symptoms — the broader the tau spread, the more severe the cognitive decline, she said.
Chang said that based on the correlation between tau protein deposition and the onset of Alzheimer’s, she hoped that in the future medical imaging for tau protein would enable earlier detection and help predict disease progression.
Current diagnostic methods for Alzheimer’s rely on assessment scales and clinical guidelines to determine whether a person “very likely” has the disease, Taiwan Dementia Society president Hsu Jung-lung (徐榮隆) said.
Biomarkers are critical to confirming an Alzheimer’s diagnosis, and such indicators could help determine whether a patient is eligible for the new treatments that might slow the disease’s progression, he said.
Jang Ming-kuei (張明奎), founder of transnational biotech company Aprinoia, said a tau protein imaging agent developed by the company can visualize tau protein accumulation in the brain, but the agent is still undergoing clinical trials.
The company is in discussions with the FDA regarding its drug approval application, including the submission of safety and efficacy data, Jang said.
An estimated 350,000 people in Taiwan have some form of dementia, with 60 to 70 percent of them having Alzheimer’s. About half, or fewer than 100,000 patients, might qualify for the new treatments, said Yan Sui-hing (甄瑞興), director of Far Eastern Memorial Hospital’s dementia center.
Restaurants in New Taipei City, Hsinchu City and Hsinchu County are to be included in the Michelin Guide’s review for the first time this year, alongside existing entries from Taipei, Taichung, Tainan and Kaohsiung, the France-based culinary publication said yesterday. This year’s edition of the Michelin Guide Taiwan is to be unveiled on Aug. 19 in Taipei. In addition to the coveted star ratings, Michelin Taiwan would announce its “Bib Gourmand” selections — a distinction awarded to establishments offering high-quality food at moderate prices — on Aug. 12. This year’s Bib Gourmand list would also feature restaurants in New Taipei City, Hsinchu
A firefighter yesterday died after falling into New Taipei City's Xindian River when a rescue dinghy capsized during a search mission for a man who was later found dead. The New Taipei City Fire Department said that it received a report at 4:12pm that a 50-year-old man, surnamed Chen (陳), had fallen into the river. A 32-year-old firefighter, surnamed Wu (吳), was among the rescuers deployed to look for Chen, the fire department said, adding that he and five other rescue personnel were in the dinghy when it capsized. Wu had no vital signs after being pulled from the water to the
Organizing one national referendum and 26 recall elections targeting Chinese Nationalist Party (KMT) legislators could cost NT$1.62 billion (US$55.38 million), the Central Election Commission said yesterday. The cost of each recall vote ranges from NT$16 million to NT$20 million, while that of a national referendum is NT$1.1 billion, the commission said. Based on the higher estimate of NT$20 million per recall vote, if all 26 confirmed recall votes against KMT legislators are taken into consideration, along with the national referendum on restarting the Ma-anshan Nuclear Power Plant, the total could be as much as NT$1.62 billion, it said. The commission previously announced
The Ministry of Foreign Affairs (MOFA) yesterday welcomed NATO Secretary-General Mark Rutte’s remarks that the organization’s cooperation with Indo-Pacific partners must be deepened to deter potential threats from China and Russia. Rutte on Wednesday in Berlin met German Chancellor Friedrich Merz ahead of a ceremony marking the 70th anniversary of Germany’s accession to NATO. He told a post-meeting news conference that China is rapidly building up its armed forces, and the number of vessels in its navy outnumbers those of the US Navy. “They will have another 100 ships sailing by 2030. They now have 1,000 nuclear warheads,” Rutte said, adding that such
RSS